Skip to Content

Female Viagra Is Found Lacking as “Predatory” Drugmaker Valeant Falls Further

The drug company has earned the ire of Hillary Clinton, is under several investigations, and was met with a collective “meh” from women who tried its “female Viagra” pill.

Democratic presidential candidate Hillary Clinton released a campaign ad promising to go after a Canadian drug company for its “predatory” price hikes, including one for a drug that increased from $180 to $14,700, according to Fortune

“The company is called Valeant Pharmaceuticals,” Clinton says in the ad. “I’m going after them.”

She’s not the only one.

The company is facing a wave of bad news: it’s under investigation by regulators in at least two states and the U.S. government, and its most notorious product—a controversial pill called the “female Viagra”—isn’t pleasing many people, either.

The drug, flibanserin, leads to only an extra “one-half” a satisfying sexual encounter per month, according to a study published on Monday.

Marketed under the name Addyi, the drug was controversial even before being approved by the U.S. Food and Drug Administration last summer, after two earlier rejections. But regulators were pressured by activist groups, who noted that there are several drugs sold to boost male sexual performance. 

Addyi treats “hypoactive sexual desire disorder,” which according to Bloomberg is “a condition marked by little or no sexual desire or fantasy life and that causes the patient distress.”

Researchers, including one who’d opposed the drug’s approval, reported this week that women taking the drug had “one-half of an additional sexually satisfying encounter per month,” leaving details of the fraction to the imagination of readers.

Since the drug has side effects, like nausea and fatigue, many experts don’t see why it was approved. Poor sales—it’s on track to bring in $11 million in 2016, versus the $100 to $150 million that Valeant initially forecast, according to the New York Times—suggest that the drug hasn’t transformed many sex lives. 

But what’s really hurting Valeant’s mojo is public outrage over the company's habit of jacking up drug prices. According to Bloomberg, the company’s stock value has fallen by more than 66 percent in recent months, and it fell even further Monday after Valeant disclosed that it was under at least four investigations by U.S. securities regulators and by Congress.

In an editorial in the Journal of the American Medical Association flush with unfortunate puns, two Dartmouth College doctors called the story of flibanserin “unsatisfying.”

“The FDA approved a marginally effective drug for a non-life-threatening condition in the face of substantial—and unnecessary—uncertainty about its dangers,” they wrote.

(Read more: Fortune, New York Times, Reuters, Bloomberg)

Keep Reading

Most Popular

open sourcing language models concept
open sourcing language models concept

Meta has built a massive new language AI—and it’s giving it away for free

Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3

transplant surgery
transplant surgery

The gene-edited pig heart given to a dying patient was infected with a pig virus

The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.

Muhammad bin Salman funds anti-aging research
Muhammad bin Salman funds anti-aging research

Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging

The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.

Yann LeCun
Yann LeCun

Yann LeCun has a bold new vision for the future of AI

One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.